IP-cure-B clinical trial

Do you know that there is a clinical trial going on in the framework of the IP-cure-B project?

The ANRS HB07 clinical trial is sponsored by ANRS | Emerging Infectious Diseases and takes place in different centres across Europe involved in the project.

The EU-funded IP-cure-B project aims to develop novel curative concepts for chronic hepatitis B (CHB). The project aims to improve the cure rate of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune responses with a novel therapeutic vaccine. Researchers will also identify immune and viral biomarkers for monitoring patient stratification and treatment response. Integrating biological and clinical data will enable models for the best combination of treatment and effectiveness of novel curative therapies concerning disease spectrum and patient heterogeneity. The preclinical platform will be evaluated in humanised mice, combining immune-modulatory strategies to stimulate innate immunity, rescue exhausted HBV-specific T cells and generate anti-HBV adaptive responses. Proof of concept will be obtained in a clinical trial of a combination of novel compounds stimulating innate immunity.

Outcomes for medical experts

The project aims at proposing a treatment paradigm shift with the development of novel combination therapies for CHB with improved cure rates and a better appraisal of novel biomarkers to improve patient selection for treatment and monitoring treatment response.

Outcomes for community

The development of such curative therapies with a finite duration of administration will pave the way towards a universal treatment of all individuals that suffer from chronic HBV infection. It is thus expected to result in a long-term reduction in cost and global burden of CHB (short-term therapy, increased treatment uptake in the infected population, decreased rate of liver complications and mortality).

Outcomes for patient

The project aims at designing and developing novel treatment strategies towards the cure of infection with a shorter duration of treatment. It is expected to improve the quality of life and decrease social stigma.

 LIST OF CLINICAL TRIAL SITES